healthstream inc. - HSTM
HSTM
Close Chg Chg %
20.30 -0.21 -1.03%
Closed Market
20.09
-0.21 (1.03%)
Volume: 487.41K
Last Updated:
Feb 6, 2026, 4:00 PM EDT
Company Overview: healthstream inc. - HSTM
HSTM Key Data
| Open $20.32 | Day Range 19.96 - 20.44 |
| 52 Week Range 19.96 - 34.24 | Market Cap $605.23M |
| Shares Outstanding 29.67M | Public Float 24.70M |
| Beta 0.44 | Rev. Per Employee N/A |
| P/E Ratio 29.75 | EPS $0.69 |
| Yield 61.08% | Dividend $0.03 |
| EX-DIVIDEND DATE Nov 17, 2025 | SHORT INTEREST N/A |
| AVERAGE VOLUME 300.47K |
HSTM Performance
| 1 Week | -9.87% | ||
| 1 Month | -9.10% | ||
| 3 Months | -18.50% | ||
| 1 Year | -39.45% | ||
| 5 Years | -19.02% |
HSTM Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
5
Full Ratings ➔
About healthstream inc. - HSTM
HealthStream, Inc. engages in the provision of services to healthcare organizations. It develops healthcare technology platforms for workforce solutions. The firm’s workforce solutions include learning management, nurse & staff scheduling, clinical education, credentialing, privileging, provider enrollment, performance assessment, and managing simulation-based education programs. The company was founded by Robert A. Frist, Jr. and Jeffery L. McLaren in 1990 and is headquartered in Nashville, TN.
HSTM At a Glance
HealthStream, Inc.
500 11th Avenue North
Nashville, Tennessee 37203-2015
| Phone | 1-615-301-3100 | Revenue | 291.65M | |
| Industry | Packaged Software | Net Income | 20.01M | |
| Sector | Technology Services | 2024 Sales Growth | 4.509% | |
| Fiscal Year-end | 12 / 2025 | Employees | 1,093 | |
| View SEC Filings |
HSTM Valuation
| P/E Current | 29.752 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 48.55 |
| Price to Sales Ratio | 3.33 |
| Price to Book Ratio | 2.693 |
| Price to Cash Flow Ratio | 16.85 |
| Enterprise Value to EBITDA | 14.301 |
| Enterprise Value to Sales | 3.066 |
| Total Debt to Enterprise Value | 0.023 |
HSTM Efficiency
| Revenue/Employee | 266,830.741 |
| Income Per Employee | 18,304.666 |
| Receivables Turnover | 8.257 |
| Total Asset Turnover | 0.57 |
HSTM Liquidity
| Current Ratio | 1.324 |
| Quick Ratio | 1.324 |
| Cash Ratio | 0.84 |
HSTM Profitability
| Gross Margin | 52.278 |
| Operating Margin | 7.299 |
| Pretax Margin | 8.504 |
| Net Margin | 6.86 |
| Return on Assets | 3.913 |
| Return on Equity | 5.715 |
| Return on Total Capital | 5.272 |
| Return on Invested Capital | 5.424 |
HSTM Capital Structure
| Total Debt to Total Equity | 5.612 |
| Total Debt to Total Capital | 5.314 |
| Total Debt to Total Assets | 3.858 |
| Long-Term Debt to Equity | 4.833 |
| Long-Term Debt to Total Capital | 4.576 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Healthstream Inc. - HSTM
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 256.71M | 266.83M | 279.06M | 291.65M | |
Sales Growth
| +4.85% | +3.94% | +4.59% | +4.51% | |
Cost of Goods Sold (COGS) incl D&A
| 127.85M | 129.09M | 136.10M | 139.18M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 36.81M | 37.95M | 41.08M | 41.24M | |
Depreciation
| 6.30M | 4.50M | 4.20M | 3.80M | |
Amortization of Intangibles
| 30.51M | 33.45M | 36.88M | 37.44M | |
COGS Growth
| +6.97% | +0.97% | +5.43% | +2.26% | |
Gross Income
| 128.87M | 137.74M | 142.97M | 152.47M | |
Gross Income Growth
| +2.84% | +6.88% | +3.80% | +6.65% | |
Gross Profit Margin
| +50.20% | +51.62% | +51.23% | +52.28% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 120.81M | 125.29M | 126.95M | 131.18M | |
Research & Development
| 41.66M | 44.28M | 45.54M | 48.89M | |
Other SG&A
| 79.15M | 81.01M | 81.41M | 82.29M | |
SGA Growth
| +10.34% | +3.71% | +1.32% | +3.33% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | 183.00K | (2.85M) | - |
EBIT after Unusual Expense
| 7.87M | 15.30M | 16.02M | 21.29M | |
Non Operating Income/Expense
| (106.00K) | 287.00K | 2.49M | 3.52M | |
Non-Operating Interest Income
| - | - | - | 3.83M | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 7.77M | 15.59M | 18.51M | 24.80M | |
Pretax Income Growth
| -56.43% | +100.68% | +18.77% | +33.99% | |
Pretax Margin
| +3.03% | +5.84% | +6.63% | +8.50% | |
Income Tax
| 1.92M | 3.49M | 3.30M | 4.80M | |
Income Tax - Current - Domestic
| 411.00K | 2.90M | 5.01M | 5.90M | |
Income Tax - Current - Foreign
| (29.00K) | (110.00K) | 15.00K | 14.00K | |
Income Tax - Deferred - Domestic
| 1.63M | 734.00K | (1.71M) | (1.05M) | |
Income Tax - Deferred - Foreign
| (86.00K) | (25.00K) | (18.00K) | (64.00K) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 5.84M | 12.09M | 15.21M | 20.01M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 5.84M | 12.09M | 15.21M | 20.01M | |
Net Income Growth
| -58.52% | +106.86% | +25.82% | +31.51% | |
Net Margin Growth
| +2.28% | +4.53% | +5.45% | +6.86% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 5.84M | 12.09M | 15.21M | 20.01M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 5.84M | 12.09M | 15.21M | 20.01M | |
EPS (Basic)
| 0.1854 | 0.3945 | 0.4976 | 0.6584 | |
EPS (Basic) Growth
| -57.95% | +112.78% | +26.13% | +32.32% | |
Basic Shares Outstanding
| 31.53M | 30.65M | 30.57M | 30.39M | |
EPS (Diluted)
| 0.1849 | 0.3936 | 0.496 | 0.655 | |
EPS (Diluted) Growth
| -58.02% | +112.87% | +26.02% | +32.06% | |
Diluted Shares Outstanding
| 31.62M | 30.72M | 30.67M | 30.54M | |
EBITDA
| 44.87M | 50.39M | 57.09M | 62.53M | |
EBITDA Growth
| -2.48% | +12.32% | +13.30% | +9.52% | |
EBITDA Margin
| +17.48% | +18.89% | +20.46% | +21.44% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 34.00 | |
| Number of Ratings | 5 | Current Quarters Estimate | 0.165 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | 0.762 | |
| Last Quarter’s Earnings | 0.08 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 0.634 | Next Fiscal Year Estimate | 0.83 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 4 | 4 | 5 | 2 |
| Mean Estimate | 0.17 | 0.19 | 0.76 | 0.83 |
| High Estimates | 0.18 | 0.21 | 0.78 | 0.87 |
| Low Estimate | 0.15 | 0.18 | 0.73 | 0.79 |
| Coefficient of Variance | 7.82 | 6.54 | 2.52 | 6.82 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 2 | 2 | 2 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 3 | 3 | 3 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Healthstream Inc. - HSTM
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Healthstream Inc. - HSTM
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 24, 2025 | Kevin P. O'Hara Executive Vice President | 2,376 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 24, 2025 | Scott Fenstermacher Senior Vice President | 1,426 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 24, 2025 | Jeffrey D. Cunningham Chief Technology Officer | 1,901 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 24, 2025 | Michael Scott McQuigg Senior Vice President | 1,901 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 24, 2025 | Trisha L. Coady Executive Vice President | 2,376 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 24, 2025 | Scott A. Roberts CFO and SVP | 1,901 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 24, 2025 | Robert A. Frist CEO and Chairman; Director | 2,376 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 24, 2025 | Michael M. Collier Executive Vice President | 2,376 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 3, 2025 | Scott Fenstermacher Senior Vice President | 12,327 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $33.15 per share | 408,640.05 |
| Feb 28, 2025 | Michael J. Sousa Executive Vice President | 65,646 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 28, 2025 | Jeffrey D. Cunningham Chief Technology Officer | 27,987 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 28, 2025 | Michael M. Collier Executive Vice President | 12,023 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 28, 2025 | Michael M. Collier Executive Vice President | 44,453 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 28, 2025 | Michael J. Sousa Executive Vice President | 39,000 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 28, 2025 | Michael J. Sousa Executive Vice President | 62,015 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $32.37 per share | 2,007,425.55 |
| Feb 28, 2025 | Michael Scott McQuigg Senior Vice President | 6,500 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 28, 2025 | Michael Scott McQuigg Senior Vice President | 23,565 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 28, 2025 | Kevin P. O'Hara Executive Vice President | 12,023 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 28, 2025 | Kevin P. O'Hara Executive Vice President | 5,490 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 28, 2025 | Scott A. Roberts CFO and SVP | 3,606 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |